- Home
- TR vs WGS Comparison
TR vs WGS Comparison
Compare TR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TR
- WGS
- Stock Information
- Founded
- TR 1896
- WGS 2017
- Country
- TR United States
- WGS United States
- Employees
- TR N/A
- WGS N/A
- Industry
- TR Specialty Foods
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- TR Consumer Staples
- WGS Technology
- Exchange
- TR Nasdaq
- WGS Nasdaq
- Market Cap
- TR 2.3B
- WGS 2.0B
- IPO Year
- TR N/A
- WGS N/A
- Fundamental
- Price
- TR $32.34
- WGS $79.20
- Analyst Decision
- TR
- WGS Strong Buy
- Analyst Count
- TR 0
- WGS 5
- Target Price
- TR N/A
- WGS $67.00
- AVG Volume (30 Days)
- TR 88.2K
- WGS 498.5K
- Earning Date
- TR 10-24-2024
- WGS 10-29-2024
- Dividend Yield
- TR 1.12%
- WGS N/A
- EPS Growth
- TR 7.80
- WGS N/A
- EPS
- TR 1.31
- WGS N/A
- Revenue
- TR $727,121,000.00
- WGS $267,228,000.00
- Revenue This Year
- TR N/A
- WGS $43.70
- Revenue Next Year
- TR N/A
- WGS $16.78
- P/E Ratio
- TR $24.30
- WGS N/A
- Revenue Growth
- TR N/A
- WGS 29.41
- 52 Week Low
- TR $27.58
- WGS $1.76
- 52 Week High
- TR $34.80
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- TR 51.78
- WGS 57.29
- Support Level
- TR $31.58
- WGS $70.69
- Resistance Level
- TR $33.27
- WGS $76.76
- Average True Range (ATR)
- TR 0.65
- WGS 6.17
- MACD
- TR -0.19
- WGS -0.34
- Stochastic Oscillator
- TR 43.68
- WGS 61.59
About TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.